Abstract:Abstract Abstract 2689 Poster Board II-665 Introduction: Extranodal NK/T-cell lymphoma (ENKL) is a distinct clinicopathological entity of non-Hodgkin's lymphoma, which is characterized by a highly aggressive clinical process and poor prognosis. There are no standard treatment strategies available now. The present study aimed to evaluate the treatment outcome and toxicity of EPOCH regimen for ENKL. Methods: From June 2003 to June 2008, 34 patients including 30 nasal ENKL (88.2%) and 4 extranasal ENKL (11.8%) received doxorubicin, vincristine, etoposide over 96 hours infusion with bolus cyclophosphamide and oral predinisone (EPOCH) combination as first-line treatment. By the Ann Arbor lymphoma Staging Classification, 29 patients (85.3%) had stage ±E-IIE disease and 5 patients (14.7%) had stage IIIE-‡WE disease. Median cycles of EPOCH regimen administered were 2.5 (range from 1 to 6 cycles). Additional involved field radiation therapy (IFRT) was administered to patients with localized regional disease after chemotherapy. Results: Among 34 patients, 33 were eligible for objective response evaluation. The response rate (RR) for the whole group was 60.6% (20/33) with complete remission (CR) rate of 45.5% (15/33). The RR of patients with nasal ENKL was 66.7% (20/30), the CR rate was 50% (15/30). Of the 4 patients with extranasal ENKL, only one achieved stable disease (SD), the other three had progressive disease (PD) during chemotherapy. After a median follow-up of 22 (2–68) months, the estimated overall 3-year overall survival rate (OS) was 52.2%. For patients with nasal ENKL, the estimated median survival time was not reached, the 3-year OS was 59.4%. For patients with extranasal ENKL, the estimated median survival time was only 7 months. For stage ±E-IIE patients with nasal ENKL who received initial EPOCH chemotherapy followed IFRT, the CR rate was 75.0%, and the 3-year survival rate was 75.0%. 102 cycles of chemotherapy were administered to 34 patients. Major adverse effect was myelosuppression. The incidence of grade III-‡W neutropenia was 30.9% and 60 cycles needed G-CSF support. Other toxicities were mild, no treatment-related mortality occurred. Conclusion: EPOCH regiment was effective on ENKL with acceptable toxlicity. EPOCH followed by IFRT yielded promising outcome for patients with localized nasal ENKL. However, patients with extranasal ENKL responded poorly, and more efficacious treatment strategies are urgently needed. Disclosures: No relevant conflicts of interest to declare.

Long-term Outcomes of Patients with Newly Diagnosed NK/T-cell Lymphoma Treated by EPOCH Regimen

Long-Term Outcomes of Patients with Newly Diagnosed Nk/T-Cell Lymphoma Treated by Epoch Regimen

Long-Term Outcomes Of Patients With Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma Treated By Etoposide, Prednisone, Vincristine, Cyclophosphamide, And Doxorubicin Regimen: A Single-Institution Experience

Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study

Preliminary Outcome for Patients with Relapsed or Resistant Advanced Non- Hodgkin' s Lymphoma Treated by EPOCH Regimen

[Clinical Outcomes of Patients with Peripheral T-cell Lymphoma (PTCL) Treated by EPOCH Regimen].

[Prognostic Analysis of Patients with Nasal-Type NK/T-cell Non-Hodgkin's Lymphoma--a Report of 93 Cases].

Preliminary Outcome of Concurrent Chemoradiation Therapy in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma

Clinical Features and Prognosis of Nasal Type NK/T Cell Lymphoma

Nasopharyngeal/Nasal Type Peripheral T-Cell Lymphomas: Long-Term Outcomes And Prognostic Analysis Of 112 Cases In Southern China.

Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (Nk/t)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study

Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

Deep Remission from Induction Chemotherapy Predicts Favorable Long-Term Survivals in Early Stage Extranodal Nasal NK/T-cell Lymphoma Receiving Sequential Chemotherapy and Radiation.

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

Radiation Therapy Alone Not Inferior to Chemoradiation in the Patients with Stage I Nasal Natural Killer/T-Cell Lymphoma

Prognostic Factors and Long-term Treatment Outcome in 64 Cases of Early Stage Nasal NK/T- cell Lymphoma